Survodutide: The Liver-Focused Dual Agonist
Boehringer Ingelheim and Zealand Pharma's 29-amino-acid GLP-1 / glucagon receptor co-agonist (formerly BI 456906). FDA Breakthrough Therapy designation for MASH.
How It Works
Activates both the GLP-1 receptor (appetite suppression, insulin secretion) and the glucagon receptor (increased energy expenditure, hepatic fat oxidation). The glucagon arm is what differentiates it from semaglutide.
Glucagon signaling raises basal metabolic rate by ~5–10% — the mechanism behind survodutide's weight loss exceeding what GLP-1 alone achieves at matched appetite suppression.
Glucagon receptors in hepatocytes drive lipid mobilization and gluconeogenesis suppression in MASH. Phase 2 showed up to 83% MASH improvement without fibrosis worsening — biopsy-confirmed.
C18 fatty-acid lipidation gives a ~7-day half-life. Phase 3 SYNCHRONIZE trials use weekly subcutaneous dosing with a slow titration to manage GI tolerability.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- Phase 2 produced 19% mean weight loss at 46 weeks — competitive with tirzepatide and approaching retatrutide.
- 83% of MASH patients showed biopsy-confirmed disease improvement at 48 weeks vs 18% on placebo.
- FDA Breakthrough Therapy designation for MASH (May 2024) — accelerates review timeline.
- Phase 3 SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (T2D + obesity), and SYNCHRONIZE-CVOT enrolled; primary completions expected 2026.
- Phase 3 LIVERAGE and LIVERAGE-Cirrhosis trials specifically target MASH/fibrosis — separate from the obesity program.
- Glucagon agonism is the differentiator: raises energy expenditure beyond what pure GLP-1 drugs achieve.
- Final Phase 3 weight-loss numbers (SYNCHRONIZE primary completion expected 2026).
- Whether glucagon-mediated effects on glycemic control are net beneficial or problematic in T2D long-term.
- Head-to-head vs retatrutide (also a glucagon-containing molecule).
- Cardiovascular outcomes (SYNCHRONIZE-CVOT readout pending).
- Long-term hepatic safety beyond 48 weeks of biopsy data.
- Whether the MASH approval will come before or alongside obesity approval.
Frequently Asked Questions
What is survodutide?
Survodutide (formerly BI 456906) is a 29-amino-acid synthetic peptide developed by Boehringer Ingelheim and Zealand Pharma. It is a dual agonist at the GLP-1 receptor (like semaglutide) and the glucagon receptor (which raises energy expenditure). Currently in Phase 3 trials for both obesity and MASH (metabolic dysfunction-associated steatohepatitis).
How does survodutide differ from semaglutide and tirzepatide?
Semaglutide is a pure GLP-1 agonist. Tirzepatide is a GLP-1/GIP dual agonist. Survodutide is a GLP-1/glucagon dual agonist — the glucagon arm directly raises basal metabolic rate and drives hepatic fat oxidation, which is why Boehringer is targeting MASH alongside obesity.
Is survodutide FDA-approved?
Not yet. As of April 2026 it remains investigational. The FDA granted Breakthrough Therapy designation for MASH in May 2024, which can accelerate review. Phase 3 SYNCHRONIZE (obesity) and LIVERAGE (MASH) trials are expected to read out in 2026, with potential approval in 2027 if data support it.
How does survodutide compare to retatrutide?
Both contain a glucagon component. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); survodutide is a dual agonist (GLP-1 + glucagon, no GIP). Retatrutide produced ~22.8% weight loss at 48 weeks in TRIUMPH-1; survodutide ~19% at 46 weeks in Phase 2. Survodutide has the lead on biopsy-proven MASH data.
What is MASH and why does survodutide target it?
MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is fatty liver disease with inflammation and fibrosis — affects ~5% of US adults. The glucagon receptor agonism in survodutide directly drives hepatic fat mobilization, mechanistically distinct from how pure GLP-1 drugs work. No GLP-1-class drug is currently FDA-approved specifically for MASH.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
Information on this page is for research and educational use only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decision related to a peptide, drug, or supplement.
HighPeptides may earn an affiliate commission from qualifying purchases via Amazon and other partner links on this page, at no extra cost to you.